Activities of 2-phthalimidethyl nitrate and 2-phthalimidethanol in the models of nociceptive response and edema induced by formaldehyde in mice and preliminary investigation of the underlying mechanisms

European Journal of Pharmacology
Adriana M GodinMárcio M Coelho

Abstract

The activities of 2-phthalimidethyl nitrate (PTD-NO) and 2-phthalimidethanol (PTD-OH) were recently demonstrated in models of pain and inflammation. We expanded our investigation by evaluating their activities in models of nociceptive and inflammatory pain and inflammatory edema, the preliminary pharmacokinetic parameter for PTD-NO and the role of opioid and cannabinoid pathways in the activity of analogs. Per os (p.o.) administration of PTD-NO or PTD-OH, 1h before intraplantar injection of formaldehyde, inhibited both phases of the nociceptive response (500 and 750 mg/kg) and paw edema (125, 250, 500 and 750 mg/kg). After p.o. administration of PTD-NO, peak plasma concentrations of PTD-NO and PTD-OH were found 0.92 and 1.13 h, respectively. The plasma concentrations of PTD-NO were higher than those of PTD-OH. Intraperitoneal (i.p.) administration of CB1 (AM251) or CB2 (AM630) cannabinoid receptor antagonists (4 or 8 mg/kg, -30 min) or opioid antagonist naltrexone (5 or 10mg/kg, -30 min) did not affect the antinociceptive activities of the analogs. AM251 (8 mg/kg, i.p., -30 min) attenuated the antiedematogenic activity of both analogs, while naltrexone (10mg/kg, i.p., -30 min) only attenuated the antiedematogenic activity of PT...Continue Reading

References

Oct 1, 1992·Pain·A TjølsenK Hole
May 1, 1990·Physiology & Behavior·C J Gordon
Aug 27, 1985·European Journal of Pharmacology·F Lembeck, J Donnerer
Apr 13, 1995·European Journal of Pharmacology·Y Hong, F V Abbott
Jan 1, 1997·Teratogenesis, Carcinogenesis, and Mutagenesis·P H Huang, W G McBride
Apr 16, 1998·Pain·Jennelle Durnett RichardsonKenneth M Hargreaves
Apr 20, 1999·Naunyn-Schmiedeberg's Archives of Pharmacology·J Damas, J F Liégeois
Aug 22, 2001·Pain·Philip T MalanAlexandros Makriyannis
Jan 30, 2002·Bioorganic & Medicinal Chemistry·Yuichi Hashimoto
Nov 8, 2002·European Journal of Pharmacology·Hans GühringKay Brune
Sep 12, 2006·European Journal of Pharmacology·Caryne M BertolloMárcio M Coelho
Aug 10, 2007·Proceedings of the National Academy of Sciences of the United States of America·Colleen R McNamaraChristopher M Fanger
Sep 14, 2007·Bioorganic & Medicinal Chemistry Letters·Scott G StewartLawrence J Abraham
Nov 3, 2007·Recent Patents on Anti-cancer Drug Discovery·Jeanny B Aragon-ChingWilliam D Figg
Dec 26, 2009·Bioorganic & Medicinal Chemistry·Scott G StewartLawrence J Abraham
Apr 21, 2010·Mini Reviews in Medicinal Chemistry·U SharmaB Singh
Sep 8, 2010·Brain Research·Christopher E HagainsYuan B Peng
Apr 19, 2011·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Gabriella AvielloRaffaele Capasso
Nov 30, 2011·Journal of Mass Spectrometry : JMS·Isabela Costa CésarGerson Antônio Pianetti
Jul 10, 2012·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Luciano MazzoccoliHenrique C Teixeira
Mar 26, 2013·Journal of the Peripheral Nervous System : JPNS·Andressa Perin-MartinsLuana Fischer
Apr 3, 2013·European Journal of Pharmacology·Rakesh B PatelMukul R Jain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.